![](https://cdn.sanity.io/images/0vv8moc6/onclive/c5e088721e8dfaaa203bfb826ed9fc5a0c74c06f-200x200.png?fit=crop&auto=format)
Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL Anymore
A hallmark of acute myeloid leukemia (AML) is a maturation arrest of myeloid-committed hematopoietic cells, and the specific sensitivity of acute promyelocytic leukemia (APL) to retinoic acid was identified in the early 1980s.1 This discovery paved the way …